NEW YORK (GenomeWeb) – Sygnis today announced it has signed a non-exclusive distribution agreement for Taiwan with Welgene Biotech.
Under the terms of the agreement, Sygnis has granted Welgene rights to promote, market, and sell TruePrime products for primer-free whole-genome analysis and SunScript thermostable reverse transcriptase kits.
"Welgene Biotech complements our fast growing list of leading international distribution partners," Sygnis CEO and CFO Pilar de la Heurta said in a statement. "The high interest and demand in our proprietary product and technology families fuel our efforts to further expand our distribution network in order to make our portfolio widely available for researchers working in the molecular biology industry throughout the world."
With offices in Heidelberg, Germany and Madrid, Spain, Sygnis specializes in developing and commercializing products for DNA amplification and sequencing.
In March, Sygnis signed a Japanese distribution deal with Funakoshi.